TY - JOUR T1 - Survivors of SARS-CoV-2 Infection Show Neuropsychiatric Sequelae Measured by Surveys, Neurocognitive Testing, and Magnetic Resonance Imaging: Preliminary Results JF - medRxiv DO - 10.1101/2021.08.23.21256078 SP - 2021.08.23.21256078 AU - Laura M. Hack AU - Jacob Brawer AU - Megan Chesnut AU - Xue Zhang AU - Max Wintermark AU - Bin Jiang AU - Philip Grant AU - Hector Bonilla AU - Patrick Stetz AU - Jerome A. Yesavage AU - Aruna Subramanian AU - Leanne M. Williams Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/26/2021.08.23.21256078.abstract N2 - A significant number of individuals experience physical, cognitive, and mental health symptoms in the months after acute infection with SARS-CoV-2, the virus that causes COVID-19. This study assessed depressive and anxious symptoms, cognition, and brain structure and function in participants with symptomatic COVID-19 confirmed by PCR testing (n=100) approximately three months following infection, leveraging self-report questionnaires, objective neurocognitive testing, and structural and functional neuroimaging data. Preliminary results demonstrated that over 1/5 of our cohort endorsed clinically significant depressive and/or anxious symptoms, and >40% of participants had cognitive impairment on objective testing across multiple domains, consistent with ‘brain-fog’. While depression and one domain of quality of life (physical functioning) were significantly different between hospitalized and non-hospitalized participants, anxiety, cognitive impairment, and most domains of functioning were not, suggesting that the severity of SARS-CoV-2 infection does not necessarily relate to the severity of neuropsychiatric outcomes and impaired functioning in the months after infection. Furthermore, we found that the majority of participants in a subset of our cohort who completed structural and functional neuroimaging (n=15) had smaller olfactory bulbs and sulci in conjunction with anosmia. We also showed that this subset of participants had dysfunction in attention network functional connectivity and ventromedial prefrontal cortex seed-based functional connectivity. These functional imaging dysfunctions have been observed previously in depression and correlated with levels of inflammation. Our results support and extend previous findings in the literature concerning the neuropsychiatric sequelae associated with long COVID. Ongoing data collection and analyses within this cohort will allow for a more comprehensive understanding of the longitudinal relationships between neuropsychiatric symptoms, neurocognitive performance, brain structure and function, and inflammatory and immune profiles.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study.Funding StatementThis study was supported through a grant from Stanfords Innovative Medicines Accelerator. LMH was supported through an Advanced Fellowship in Mental Illness Research and Treatment through The Office of Academic Affiliations, Department of Veterans Affairs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Stanford University has approved this protocol (#57070). A study coordinator thoroughly explained the protocol to patients and answered any questions before they provided written informed consent to begin the study. The study was conducted according to the principles of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collection is ongoing. Data will be made publicly available once data collection has been completed. ER -